# HMGN2

## Overview
HMGN2 is a gene that encodes the high mobility group nucleosomal binding domain 2 protein, a non-histone chromosomal protein involved in the regulation of chromatin structure and gene expression. The HMGN2 protein is characterized by its ability to bind specifically to nucleosomes, influencing chromatin dynamics by competing with linker histone H1, thereby reducing chromatin compaction and facilitating transcription factor recruitment (Postnikov2010Regulation). This protein plays a crucial role in maintaining active chromatin states and is involved in various cellular processes, including differentiation and development (Furusawa2010Developmental). HMGN2 is also implicated in clinical contexts, such as breast cancer progression and erythropoiesis, where its interactions and modifications can significantly impact disease outcomes (Clevenger2017Abstract; Kretov2024The).

## Structure
HMGN2 is a non-histone chromosomal protein that plays a role in modulating chromatin structure. The primary structure of HMGN2 includes a sequence of amino acids that form specific domains crucial for its function. The nucleosome binding domain (NBD) of HMGN2, comprising residues 19-42, is essential for its interaction with the nucleosome core, rather than the histone tails (Kato2011Architecture). This domain includes an N-terminal Arg-rich region that interacts with the acidic patch of the H2A-H2B dimer and a C-terminal Lys-rich portion that binds to DNA near the entry/exit point (Kato2011Architecture).

The secondary structure of HMGN2 features a transmembrane α-helical structure, identified as the putative antimicrobial domain located between positions 18 to 48. This α-helical domain exhibits strong antimicrobial activity against certain antibiotic-resistant strains (FENG2005alphaHelical). The extended conformation of the NBD is maintained by Pro residues, which help reduce the entropic cost of binding (Kato2011Architecture).

Post-translational modifications, such as phosphorylation of Ser24 and Ser28, can destabilize the HMGN2-nucleosome complex, suggesting a regulatory mechanism during mitosis (Kato2011Architecture). The tertiary and quaternary structures of HMGN2 are not detailed in the provided context.

## Function
HMGN2 is a non-histone chromosomal protein that plays a significant role in modulating chromatin structure and influencing gene expression. It binds specifically to nucleosomes, affecting chromatin dynamics by competing with linker histone H1 for binding sites, which reduces chromatin compaction and facilitates the recruitment of transcription factors (Postnikov2010Regulation). HMGN2 is involved in maintaining active chromatin states by promoting histone modifications such as acetylation of histone H3 lysine 14 (H3K14ac), which is crucial for gene expression and cellular differentiation (Furusawa2010Developmental; Postnikov2010Regulation).

In pluripotent stem cells, HMGN2 is essential for maintaining stem cell identity by preserving an epigenetic landscape conducive to pluripotency. It prevents spontaneous differentiation by maintaining active histone marks at promoters and enhancers of key pluripotency genes like Nanog and Oct4 (GarzaManero2019Maintenance). HMGN2's role in chromatin remodeling and gene regulation is critical for normal cellular processes, including differentiation and development, as its misregulation can lead to developmental abnormalities (Furusawa2010Developmental). In adult tissues, HMGN2 supports neural stem cell function and differentiation, highlighting its role in neurogenic niches (GarzaManero2019Maintenance).

## Clinical Significance
HMGN2 plays a significant role in breast cancer progression through its interaction with HDAC6 and the transcription factor Stat5a. HDAC6 deacetylates HMGN2, enhancing its binding to chromatin and facilitating Stat5a-mediated transcription, which promotes breast cancer growth. Inhibition of HDAC6 increases HMGN2 acetylation, reducing Stat5a activity and tumor growth, suggesting that targeting HMGN2 deacetylation could be a therapeutic strategy in breast cancer (Clevenger2017Abstract). The deacetylation of HMGN2 at residue K2 is crucial for Stat5a-mediated transcription of genes like CISH, which are involved in tumorigenic processes (Clevenger2017Abstract).

In erythropoiesis, the miR-144/HMGN2 regulatory axis is critical for chromatin organization. miR-144 targets HMGN2, and its loss leads to impaired chromatin condensation during erythrocyte maturation. This disruption can result in conditions related to erythropoiesis, such as anemia or myelodysplastic syndromes. Reducing HMGN2 activity can restore normal erythrocyte maturation in miR-144 mutants, highlighting its role in erythropoietic defects (Kretov2024The). These findings underscore the clinical significance of HMGN2 in both cancer and blood disorders, where its expression and interactions are altered.

## Interactions
HMGN2 is a non-histone chromosomal protein that specifically binds to nucleosome core particles, the fundamental units of chromatin, through its nucleosomal binding domain (NBD). This domain contains an essential octapeptide motif, RRSARLSA, which is crucial for its specific interaction with nucleosomes (Postnikov2010Regulation; Gerlitz2009The). HMGN2 forms homodimeric complexes on nucleosomes, meaning two molecules of HMGN2 bind to a single nucleosome core particle (Gerlitz2009The).

HMGN2 competes with linker histone H1 for binding sites on chromatin, reducing chromatin compaction and facilitating the targeting of regulatory factors to chromatin (Postnikov2010Regulation; Catez2004Network). This competition with histone H1 is a key aspect of its role in modulating chromatin structure and function (Postnikov2010Regulation).

HMGN2 is also involved in interactions with chromatin remodeling complexes, affecting nucleosome positioning and histone modifications, which are crucial for transcription regulation (Postnikov2010Regulation). It does not directly compete with proteins from other HMG families, such as HMGB1, for chromatin binding sites, indicating distinct binding preferences (Catez2004Network).


## References


[1. (Furusawa2010Developmental) Takashi Furusawa and Srujana Cherukuri. Developmental function of hmgn proteins. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1799(1–2):69–73, January 2010. URL: http://dx.doi.org/10.1016/j.bbagrm.2009.11.011, doi:10.1016/j.bbagrm.2009.11.011. This article has 33 citations.](https://doi.org/10.1016/j.bbagrm.2009.11.011)

[2. (Gerlitz2009The) Gabi Gerlitz, Robert Hock, Tetsuya Ueda, and Michael Bustin. The dynamics of hmg protein–chromatin interactions in living cellsthis paper is one of a selection of papers published in this special issue, entitled csbmcb’s 51st annual meeting – epigenetics and chromatin dynamics, and has undergone the journal’s usual peer review process. Biochemistry and Cell Biology, 87(1):127–137, February 2009. URL: http://dx.doi.org/10.1139/o08-110, doi:10.1139/o08-110. This article has 61 citations.](https://doi.org/10.1139/o08-110)

[3. (GarzaManero2019Maintenance) Sylvia Garza-Manero, Abdulmajeed Abdulghani A. Sindi, Gokula Mohan, Ohoud Rehbini, Valentine H. M. Jeantet, Mariarca Bailo, Faeezah Abdul Latif, Maureen P. West, Ross Gurden, Lauren Finlayson, Silvija Svambaryte, Adam G. West, and Katherine L. West. Maintenance of active chromatin states by hmgn2 is required for stem cell identity in a pluripotent stem cell model. Epigenetics &amp; Chromatin, December 2019. URL: http://dx.doi.org/10.1186/s13072-019-0320-7, doi:10.1186/s13072-019-0320-7. This article has 22 citations.](https://doi.org/10.1186/s13072-019-0320-7)

[4. (Kato2011Architecture) Hidenori Kato, Hugo van Ingen, Bing-Rui Zhou, Hanqiao Feng, Michael Bustin, Lewis E. Kay, and Yawen Bai. Architecture of the high mobility group nucleosomal protein 2-nucleosome complex as revealed by methyl-based nmr. Proceedings of the National Academy of Sciences, 108(30):12283–12288, July 2011. URL: http://dx.doi.org/10.1073/pnas.1105848108, doi:10.1073/pnas.1105848108. This article has 150 citations.](https://doi.org/10.1073/pnas.1105848108)

[5. (Catez2004Network) Frédéric Catez, Huan Yang, Kevin J. Tracey, Raymond Reeves, Tom Misteli, and Michael Bustin. Network of dynamic interactions between histone h1 and high-mobility-group proteins in chromatin. Molecular and Cellular Biology, 24(10):4321–4328, May 2004. URL: http://dx.doi.org/10.1128/mcb.24.10.4321-4328.2004, doi:10.1128/mcb.24.10.4321-4328.2004. This article has 202 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.24.10.4321-4328.2004)

[6. (Postnikov2010Regulation) Yuri Postnikov and Michael Bustin. Regulation of chromatin structure and function by hmgn proteins. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1799(1–2):62–68, January 2010. URL: http://dx.doi.org/10.1016/j.bbagrm.2009.11.016, doi:10.1016/j.bbagrm.2009.11.016. This article has 72 citations.](https://doi.org/10.1016/j.bbagrm.2009.11.016)

[7. (Kretov2024The) Dmitry A. Kretov, Leighton Folkes, Alexandra Mora-Martin, Isha A. Walawalkar, Imrat, Noreen Syedah, Kim Vanuytsel, Simon Moxon, George J. Murphy, and Daniel Cifuentes. The mir-144/hmgn2 regulatory axis orchestrates chromatin organization during erythropoiesis. Nature Communications, May 2024. URL: http://dx.doi.org/10.1038/s41467-024-47982-2, doi:10.1038/s41467-024-47982-2. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-024-47982-2)

[8. (Clevenger2017Abstract) CV Clevenger, JM Craig, AA Fiorillo, YB Feeney, JC Harrell, and TR Medler. Abstract p3-06-08: hdac6 deacetylates hmgn2 to regulate stat5a activity and breast cancer growth. Cancer Research, 77(4_Supplement):P3-06-08-P3-06–08, February 2017. URL: http://dx.doi.org/10.1158/1538-7445.sabcs16-p3-06-08, doi:10.1158/1538-7445.sabcs16-p3-06-08. This article has 0 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1538-7445.sabcs16-p3-06-08)

[9. (FENG2005alphaHelical) Yun FENG, Ning HUANG, Qi WU, Lang BAO, and Bo-yao WANG. Alpha-helical domain is essential for antimicrobial activity of high mobility group nucleosomal binding domain 2 (hmgn2)1. Acta Pharmacologica Sinica, 26(9):1087–1092, September 2005. URL: http://dx.doi.org/10.1111/j.1745-7254.2005.00132.x, doi:10.1111/j.1745-7254.2005.00132.x. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1745-7254.2005.00132.x)